DelveInsight’s “Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the HABP/VABP market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging HABP/VABP drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current HABP/VABP treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP): An Overview
Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP), are the most common infections in hospitalized patients, particularly those in the intensive care units. They are associated with high mortality, economic costs, and antibacterial drug resistance.
Bacterial Pneumonia is frequently categorized based on the site of acquisition. Hospital-acquired (or nosocomial) pneumonia is pneumonia that occurs 48 hours or more after admission and does not appear to be incubating at the time of admission. While ventilator-associated pneumonia is a type of HABP that develops more than 48 hours after endotracheal intubation.
It develops in the hospital environment, so causative pathogens do include multidrug-resistant organisms that require novel antimicrobials. Common pathogens of HABP/VABP include aerobic gram-negative bacilli (Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp, Acinetobacter spp) and gram-positive cocci (Staphylococcus aureus, which includes methicillin-resistant S.aureus, Streptococcus sp.). Differences in host factors and the hospital flora affect the patterns of the causative pathogens. Of these, S.aureus, P.aeruginosa, E.coli, Klebsiella, Acinetobacter, and Enterobacter species cause nearly 80% of all HABP or VABP episodes.
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Market Key Facts
According to various studies the pathogens most likely to cause HABP/VABP include S.aureus, P.aeruginosa, Klebsiella, E.coli, Acinetobacter species, and Enterobacter species.
According to the CDC, 1.5 million people were diagnosed with pneumonia in an emergency department in 2018.
According to a retrospective cohort-based study by Zilberberg et al. (2022), among 17,819 patients who met enrollment criteria, 26.5% had non-ventilated HABP, 25.6% had ventilated hospital-acquired bacterial pneumonia, and 47.9% had VABP. Ventilated HABP was associated with the highest comorbidity burden and VABP with the lowest. Among survivors, 24.5% of non-ventilated HABP required re-hospitalization within 30 days of discharge, compared with 22.5% among ventilated HABP and 18.8% VABP. Both HABP and VABP remain associated with significant mortality and cost in the US.
According to a study by Kalanuria et al. (2014), VABP is estimated to occur in 9-27 % of all mechanically ventilated patients, with the highest risk being early in the course of hospitalization. It is the second most common nosocomial infection in the ICU and the most common in mechanically ventilated patients.
A study by Ericson et al. (2021) described the epidemiology of pediatric HABP/VABP, among 862 participants. This included neonates, infants, and children. The overall HABP/VABP incidence observed was 1.9 HABP/VABP cases per 1000 ICU days overall. HABP/VABP occurred in 10% of patients receiving respiratory support in all age groups. While the VABP rate was 3.9 cases per 1000 ventilator days overall. For those who only received non-invasive mechanical ventilation, HABP/VABP occurred in 12%.
According to a retrospective large-scale Japanese claims database-based study by Kimata et al. (2021), most HABP episodes (77.6%) occurred more than 5 days after hospitalization. During the 12-month pre-index period including outpatients, 84.9% of patients had some type of pneumonia record, 9.1% had VABP, and 7.4% had anti-MRSA prescription records.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging HABP/VABP pipeline therapies. It also thoroughly assesses the HABP/VABP market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed HABP/VABP drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Hospital-acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted HABP/VABP epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted HABP/VABP epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the HABP/VABP Epidemiology, Segmented as –
Total Incident Cases of Bacterial Pneumonia in the 7MM (2019-32)
Total Incident Cases of HABP/VABP in the 7MM (2019-32)
Etiology-specific Cases of HABP/VABP in the 7MM (2019-32)
Treated Cases of HABP/VABP in the 7MM (2019-32)
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the HABP/VABP market or expected to be launched during the study period. The analysis covers the HABP/VABP market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the HABP/VABP drugs based on their sale and market share.
The report also covers the HABP/VABP pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key HABP/VABP companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the HABP/VABP Market Will Evolve and Grow by 2032 @
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Therapeutics Analysis
The mortality associated with hospital-acquired pneumonia is high despite the availability of effective antibiotics. The various therapies approved by the US FDA for the treatment of HABP/VABP include Merck’s ZERBAXA and RECARBRIO, Shionogi’s FETROJA, Melinta Therapeutics’ VABOMERE, Cumberland Pharmaceuticals’ VIBATIV, and AbbVie’s/ Pfizer’s AVYCAZ/ ZAVICEFTA. However there is still a need for therapies that address the increasing antimicrobial resistance and are effective treatments against a wide spectrum of bacteria.
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Companies Actively Working in the Therapeutics Market Include
And Many Others
Emerging and Marketed Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Therapies Covered in the Report Include:
ZERBAXA and RECARBRIO: Merck
VABOMERE: Melinta Therapeutics
VIBATIV: Cumberland Pharmaceuticals
AVYCAZ/ ZAVICEFTA: AbbVie’s/ Pfizer
AR-301 (tosatoxumab): Aridis Pharmaceuticals
OMN6: Omnix Medical
RG6006 (Abx MCP)/RO7223280: Roche
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. HABP/VABP Competitive Intelligence Analysis
4. HABP/VABP Market Overview at a Glance
5. HABP/VABP Disease Background and Overview
6. HABP/VABP Patient Journey
7. HABP/VABP Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. HABP/VABP Treatment Algorithm, Current Treatment, and Medical Practices
9. HABP/VABP Unmet Needs
10. Key Endpoints of HABP/VABP Treatment
11. HABP/VABP Marketed Therapies
12. HABP/VABP Emerging Drugs and Latest Therapeutic Advances
13. HABP/VABP Seven Major Market Analysis
14. Attribute Analysis
15. HABP/VABP Market Outlook (In US, EU5, and Japan)
16. HABP/VABP Companies Active in the Market
17. HABP/VABP Access and Reimbursement Overview
18. KOL Views on the HABP/VABP Market
19. HABP/VABP Market Drivers
20. HABP/VABP Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Inguinal Hernia Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Inguinal Hernia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Inguinal Hernia market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States